571 related articles for article (PubMed ID: 23195016)
1. Treatment of anemia with erythropoietin-stimulating agents in kidney transplant recipients and chronic kidney disease-another drawback of immunosuppression?
Malyszko J; Glowinska I; Mysliwiec M
Transplant Proc; 2012 Dec; 44(10):3013-6. PubMed ID: 23195016
[TBL] [Abstract][Full Text] [Related]
2. Anemia in kidney transplants without erythropoietic agents: levels of erythropoietin and iron parameters.
Florit EA; Hadad F; Rodriguez Cubillo B; De la Flor JC; Valga F; Perez Flores I; Calvo Romero N; Valero San Cecilio R; Barrientos Guzman A; Sanchez Fructuoso A
Transplant Proc; 2012 Nov; 44(9):2590-2. PubMed ID: 23146464
[TBL] [Abstract][Full Text] [Related]
3. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
Luna E; Cerezo I; Macias R; Villa J; Martinez C; Cubero J; Martinez R; Ferreira F; García C
Transplant Proc; 2011; 43(6):2187-90. PubMed ID: 21839229
[TBL] [Abstract][Full Text] [Related]
4. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
5. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
6. [Incidence and management of anemia in renal transplantation: an observational-French study].
Choukroun G; Deray G; Glotz D; Lebranchu Y; Dussol B; Bourbigot B; Lefrançois N; Cassuto-Viguier E; Toupance O; Hacen C; Lang P; Mazouz H; Martinez F
Nephrol Ther; 2008 Dec; 4(7):575-83. PubMed ID: 18672417
[TBL] [Abstract][Full Text] [Related]
7. Proteinuria is a predictor of posttransplant anemia.
Bonofiglio R; Lofaro D; Greco R; Senatore M; Papalia T
Transplant Proc; 2011 May; 43(4):1063-6. PubMed ID: 21620053
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Tonelli M; Garg AX; Pellegrini F; Ravani P; Jardine M; Perkovic V; Graziano G; McGee R; Nicolucci A; Tognoni G; Strippoli GF
Ann Intern Med; 2010 Jul; 153(1):23-33. PubMed ID: 20439566
[TBL] [Abstract][Full Text] [Related]
10. Impact of very early high doses of recombinant erythropoietin on anemia and allograft function in de novo kidney-transplant patients.
Kamar N; Reboux AH; Cointault O; Esposito L; Cardeau-Desangles I; Lavayssière L; Guitard J; Wéclawiak H; Rostaing L
Transpl Int; 2010 Mar; 23(3):277-84. PubMed ID: 19821956
[TBL] [Abstract][Full Text] [Related]
11. Anemia control in renal transplant recipients receiving continuous erythropoietin receptor activator (C.E.R.A.) treatment: the AnemiaTrans Study.
Sánchez-Fructuoso AI; Ruiz JC; Torregrosa JV; González E; Gómez E; Gallego RJ; Troya MI; Jimenez C; Llamas F; Romero R; Bernis C; Crespo JF; Guirado L;
Adv Ther; 2012 Nov; 29(11):979-91. PubMed ID: 23160946
[TBL] [Abstract][Full Text] [Related]
12. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
[TBL] [Abstract][Full Text] [Related]
13. Anemia after kidney transplantation; its prevalence, risk factors, and independent association with graft and patient survival: a time-varying analysis.
Jones H; Talwar M; Nogueira JM; Ugarte R; Cangro C; Rasheed H; Klassen DK; Weir MR; Haririan A
Transplantation; 2012 May; 93(9):923-8. PubMed ID: 22377790
[TBL] [Abstract][Full Text] [Related]
14. Long-acting erythropoietin stimulating agents for persistent anemia after kidney transplant: risk factors and outcome.
Al-Otaibi T; Gheith O; Halim MA; Abu Attia H; Mansour H; Said T; Nair P; Balaha M; Nampoory MR
Exp Clin Transplant; 2014 Jun; 12(3):220-6. PubMed ID: 24907722
[TBL] [Abstract][Full Text] [Related]
15. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
[TBL] [Abstract][Full Text] [Related]
16. Management of chronic kidney disease after renal transplantation: is it different from nontransplant patients?
Jiménez Alvaro S; Marcén R; Teruel JL; Fernández Rodríguez A; Pascual J; Galeano C; Villacorta J; Burgos FJ; Ortuño J
Transplant Proc; 2009; 41(6):2409-11. PubMed ID: 19715935
[TBL] [Abstract][Full Text] [Related]
17. [Long-acting erythropoetin efficacy in the treatment of nephrogenic anemia in patients with chronic kidney disease during predialysis stage].
Milovanov IuS; Milovanova LIu
Ter Arkh; 2012; 84(6):48-52. PubMed ID: 22997919
[TBL] [Abstract][Full Text] [Related]
18. Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study.
Tsuruya K; Hayashi T; Yamamoto H; Hase H; Nishi S; Yamagata K; Nangaku M; Wada T; Uemura Y; Ohashi Y; Hirakata H;
Clin Exp Nephrol; 2021 May; 25(5):456-466. PubMed ID: 33411115
[TBL] [Abstract][Full Text] [Related]
19. Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin.
Tsuruya K; Yoshida H; Suehiro T; Fujisaki K; Masutani K; Kitazono T
Ren Fail; 2016; 38(3):390-6. PubMed ID: 26822074
[TBL] [Abstract][Full Text] [Related]
20. Is the problem with the vehicle or the destination? Does high-dose ESA or high haemoglobin contribute to poor outcomes in CKD?
Badve SV; Hawley CM; Johnson DW
Nephrology (Carlton); 2011 Feb; 16(2):144-53. PubMed ID: 21272125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
